Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Nuclear Medicine

  Free Subscription

Articles published in Lancet

Retrieve available abstracts of 7 articles:
HTML format

Single Articles

    April 2024
  1. PEREZ-GARCIA JM, Cortes J, Ruiz-Borrego M, Colleoni M, et al
    3-year invasive disease-free survival with chemotherapy de-escalation using an (18)F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
    Lancet. 2024 Apr 3:S0140-6736(24)00054-0. doi: 10.1016/S0140-6736(24)00054.
    PubMed     Abstract available

    February 2024
  2. BAYAS A, Menacher M, Lapa C, Tappe D, et al
    (18)fluorodeoxyglucose PET/CT as possible early diagnostic tool preceding MRI changes in Borna disease virus 1 encephalitis.
    Lancet. 2024;403:665-666.

    December 2023
  3. TSAI CJ, Yang JT, Shaverdian N, Patel J, et al
    Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomi
    Lancet. 2023 Dec 14:S0140-6736(23)01857-3. doi: 10.1016/S0140-6736(23)01857.
    PubMed     Abstract available

    March 2022
  4. YEN HL, Sit THC, Brackman CJ, Chuk SSY, et al
    Transmission of SARS-CoV-2 delta variant (AY.127) from pet hamsters to humans, leading to onward human-to-human transmission: a case study.
    Lancet. 2022;399:1070-1078.
    PubMed     Abstract available

    August 2021
  5. TZOLOS E, Bing R, Newby DE, Dweck MR, et al
    Categorising myocardial infarction with advanced cardiovascular imaging.
    Lancet. 2021;398:e9.

    May 2021
  6. JANI AB, Schreibmann E, Goyal S, Halkar R, et al
    (18)F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial.
    Lancet. 2021 May 7. pii: S0140-6736(21)00581.
    PubMed     Abstract available

    February 2021
  7. HOFMAN MS, Emmett L, Sandhu S, Iravani A, et al
    [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
    Lancet. 2021;397:797-804.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Nuclear Medicine is free of charge.